MALARIA

This early-stage trial tests a new malaria vaccine made from live but genetically weakened malaria parasites. The goal is to see if it is safe and triggers a strong immune response. Up to 22 healthy adults who have never had malaria will receive the vaccine or a placebo, then be …

This large-scale study tests the R21/Matrix-M vaccine to prevent malaria in 4,800 children aged 5-36 months living in Africa. The vaccine aims to protect against the most dangerous form of malaria. Researchers will measure how well it works and check for side effects over one yea…

This study tests a new malaria vaccine called SUM-101 in 69 healthy children and infants aged 5 months to 5 years in Burkina Faso. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive three doses, and some infants also receive a ra…

This study tests the R21/Matrix-M1 malaria vaccine in 330 healthy women aged 18–35 in Mali who may become pregnant. Participants receive two or three doses of the vaccine or a placebo, and are followed for two years to check safety, immune response, and whether they get malaria. …

This study tests whether an experimental malaria vaccine (PfSPZ) is safe for pregnant women. Malaria can cause serious harm during pregnancy, including miscarriage and early delivery. The trial involves 400 healthy pregnant women in Mali who will receive either the vaccine or a p…

This trial compares two new types of insecticide-treated bed nets against standard nets to see if they better prevent malaria in children aged 6 months to 10 years in central Côte d'Ivoire. About 1,650 people are taking part across multiple villages. The new nets contain either a…

This Phase 3 trial in Uganda tests whether giving young children monthly malaria prevention medicine (dihydroartemisinin-piperaquine) from 8 weeks to 1 or 2 years of age helps them develop stronger immunity against malaria later. 924 children are enrolled and followed until age 4…

This study tests whether giving school children preventive malaria medicine can reduce infections not only in them but also in younger siblings at home. About 1,000 students in rural Malawi will receive either one of two drug combinations or no preventive treatment. Researchers w…

This study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.

This study was designed to test whether giving a lab-made antibody (L9LS) before a malaria vaccine (R21/Matrix-M) changes how well the vaccine works. It planned to enroll healthy adults and infants in Mali. However, the study was withdrawn before any participants were enrolled, s…

This study tracks how often people of all ages in two Liberian villages get malaria, and how many mosquitoes carry the parasite. Researchers will test blood samples monthly and collect mosquitoes from homes. The goal is to gather data that could help decide the best way to use a …